Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Call Options Transaction History
Slate Path Capital LP
- $5.09 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARWR
# of Institutions
293Shares Held
91.6MCall Options Held
1.33MPut Options Held
549K-
Black Rock Inc. New York, NY15.7MShares$302 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$235 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$171 Million3.15% of portfolio
-
State Street Corp Boston, MA5.84MShares$112 Million0.01% of portfolio
-
Artal Group S.A. Luxembourg, N43.19MShares$61.3 Million5.25% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.04B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...